Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
20 Novembro 2024 - 10:30AM
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp.
(NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage
biotech developing RNA interference (RNAi) therapies for
KRAS-driven cancers, today announced that the Company’s management
will be attending and presenting at the Noble Capital Markets 20th
Annual Emerging Growth Equity Conference taking place December 3-4,
2024, in Boca Raton, Florida.
Ilan Hadar, Chief Executive Officer will deliver a company
presentation titled “Transforming Cancer Care: Silexion
Therapeutics’ Innovative Approach to Pancreatic Cancer” on December
4, 2024 at 11:30 am. A replay of the presentation will be posted,
when available, to Silexion’s website on the Presentation &
Events page of the investors section.
The Company’s management team will be available for one-on-one
meetings throughout the summit. Interested investors are encouraged
to contact the Noble investor outreach team to schedule a
meeting.
About Silexion Therapuetics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering
clinical-stage, oncology-focused biotechnology company developing
innovative RNA interference (RNAi) therapies to treat solid tumors
driven by KRAS mutations, the most common oncogenic driver in human
cancers. The company's first-generation product, LODER™, has shown
promising results in a Phase 2 trial for non-resectable pancreatic
cancer. Silexion is also advancing its next-generation siRNA
candidate, SIL-204, designed to target a broader range of KRAS
mutations and showing significant potential in preclinical studies.
The company remains committed to pushing the boundaries of
therapeutic innovation in oncology, with a focus on improving
outcomes for patients with difficult-to-treat cancers. For more
information please visit: https://silexion.com
Company ContactSilexion Therapeutics CorpMs.
Mirit Horenshtein Hadar, CFOmirit@silexion.com
Investor ContactARX | Capital Markets
AdvisorsNorth American Equities Desksilexion@arxadvisory.com
Silexion Therapeutics (NASDAQ:SLXN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Silexion Therapeutics (NASDAQ:SLXN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
